Scientists Revive Phage Therapy in Battle Against Superbugs

An international consortium has received €1.2 million from the European Union to enhance research into phage therapy as a potential solution to combat antibiotic resistance, a growing global health threat. The World Health Organization has warned that antibiotic resistance could lead to 208 million deaths in the next 25 years.

Phage therapy utilizes bacteriophage viruses, which specifically target and kill bacteria without harming human cells. Despite its success in treating countless patients over the last century, phage therapy has remained underutilized due to limited knowledge and regulatory challenges. Recent studies show a resurgence of interest in phage therapy in the U.S., Europe, and the Middle East, with notable developments such as the establishment of national phage banks and dedicated research centers.

Microbiologist María del Mar Tomás from A Coruña University Hospital emphasizes the environmental ubiquity of phages, with trillions existing globally. While phages have shown efficacy in personalized treatments, particularly in cases where conventional antibiotics have failed, challenges such as bacterial resistance and the need for tailored therapies persist.

Recent reports suggest significant clinical improvement in over 79% of treated patients, with minimal adverse effects. However, skepticism remains regarding the efficacy of phage therapy in broader clinical trials. Experts stress the importance of further research and developing a robust regulatory framework to unlock the full potential of this innovative therapeutic approach against multi-resistant bacteria.